C4 Therapeutics, Inc. 8-K

What Happened
C4 Therapeutics, Inc. announced its financial results and business highlights for the quarter and fiscal year ended December 31, 2025 in a press release dated February 26, 2026. The company furnished that press release as Exhibit 99.1 to a Current Report on Form 8‑K (Item 2.02 - Results of Operations and Financial Condition). The Form 8‑K also includes the Interactive XBRL cover page (Exhibit 104) and is signed by Kendra R. Adams, Chief Financial Officer and Treasurer.

Key Details

• Filing date: February 26, 2026 (Form 8‑K furnished on that date).
• Reporting period: Quarter and fiscal year ended December 31, 2025.
• Exhibit 99.1: Press release announcing the results and business highlights is furnished with the 8‑K.
• Exhibit 104: Cover Page Interactive Data File (Inline XBRL) is included.
• Report signed by CFO Kendra R. Adams.

Why It Matters
This 8‑K provides investors with C4 Therapeutics’ most recent earnings and operational update for Q4 and FY2025. Retail investors should review the furnished press release (Exhibit 99.1) for specific figures—such as revenue, net income/loss, cash position, and any business milestones—that could affect valuation and near‑term expectations. The filing confirms the company has publicly released its quarterly and full‑year results and made the underlying data available in interactive XBRL format for analysis.